Header Logo

Melody Cobleigh

Concepts (330)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
68
2022
409
7.780
Why?
Receptor, ErbB-2
19
2022
51
3.540
Why?
Trastuzumab
17
2021
26
2.160
Why?
Antineoplastic Agents
20
2019
198
2.150
Why?
Antineoplastic Combined Chemotherapy Protocols
20
2022
245
1.490
Why?
Drug Resistance, Neoplasm
2
2020
69
1.250
Why?
Antibodies, Monoclonal
14
2011
177
1.160
Why?
Biomarkers, Tumor
9
2019
205
1.130
Why?
Neoplasm Metastasis
19
2019
107
0.960
Why?
Female
72
2022
15213
0.870
Why?
Antineoplastic Agents, Immunological
2
2020
15
0.840
Why?
Carcinoma, Intraductal, Noninfiltrating
2
2021
12
0.830
Why?
Mastectomy, Segmental
3
2021
29
0.770
Why?
STAT6 Transcription Factor
1
2020
11
0.690
Why?
Humans
78
2022
27074
0.660
Why?
Breast Neoplasms, Male
1
2019
11
0.660
Why?
Antibodies, Monoclonal, Humanized
17
2014
85
0.650
Why?
Class Ia Phosphatidylinositol 3-Kinase
1
2019
4
0.640
Why?
Protein Kinase Inhibitors
2
2019
53
0.640
Why?
Middle Aged
44
2021
8923
0.630
Why?
MAP Kinase Signaling System
1
2019
36
0.630
Why?
Central Nervous System Neoplasms
1
2018
11
0.620
Why?
Tamoxifen
7
2012
30
0.560
Why?
Aromatase Inhibitors
4
2012
8
0.560
Why?
ErbB Receptors
3
2008
54
0.540
Why?
Antineoplastic Agents, Hormonal
3
2012
18
0.480
Why?
Adult
37
2020
7831
0.470
Why?
Aged
34
2020
8997
0.440
Why?
Molecular Targeted Therapy
2
2016
33
0.440
Why?
Receptors, Progesterone
7
2019
26
0.430
Why?
Carcinoma
2
2011
67
0.420
Why?
Estrogen Replacement Therapy
3
1999
19
0.420
Why?
Aged, 80 and over
18
2020
4777
0.410
Why?
Enzyme Inhibitors
4
2006
114
0.400
Why?
Chemotherapy, Adjuvant
10
2016
81
0.380
Why?
Angiogenesis Inhibitors
3
2014
15
0.350
Why?
Cell Proliferation
3
2020
175
0.340
Why?
Hypertension
3
2014
192
0.310
Why?
Cell Line, Tumor
2
2020
256
0.310
Why?
Receptors, Estrogen
8
2013
65
0.310
Why?
Neoplasm Staging
11
2019
363
0.300
Why?
Treatment Outcome
14
2021
3485
0.300
Why?
Prospective Studies
5
2021
1778
0.290
Why?
Menopause
2
2000
101
0.290
Why?
Ventricular Dysfunction, Left
2
2019
34
0.290
Why?
Prognosis
7
2018
785
0.280
Why?
Neoplasm Recurrence, Local
6
2019
206
0.260
Why?
Genes, BRCA2
3
2020
10
0.250
Why?
Genes, BRCA1
3
2020
12
0.250
Why?
Disease-Free Survival
6
2017
174
0.240
Why?
Ovarian Neoplasms
3
2019
72
0.230
Why?
Registries
3
2021
189
0.230
Why?
Survival Analysis
7
2018
257
0.230
Why?
Survival Rate
5
2019
342
0.220
Why?
Angina Pectoris
1
2004
16
0.220
Why?
Postmenopause
5
2010
54
0.220
Why?
Young Adult
2
2019
1994
0.210
Why?
Quinazolines
2
2016
16
0.200
Why?
Cancer Survivors
1
2022
12
0.200
Why?
Quality of Life
9
2007
629
0.200
Why?
Quinolines
2
2022
8
0.190
Why?
Follow-Up Studies
6
2019
1792
0.190
Why?
Combined Modality Therapy
5
2018
300
0.190
Why?
Bevacizumab
7
2014
21
0.180
Why?
Carcinoma, Squamous Cell
3
1987
172
0.180
Why?
Head and Neck Neoplasms
3
1987
149
0.180
Why?
Immunohistochemistry
5
2017
366
0.180
Why?
Vascular Endothelial Growth Factor A
2
2013
75
0.170
Why?
Disease Progression
7
2011
673
0.170
Why?
Germ-Line Mutation
1
2020
14
0.170
Why?
Epithelial-Mesenchymal Transition
1
2020
6
0.170
Why?
Menopause, Premature
2
2000
7
0.170
Why?
Stroke Volume
2
2019
54
0.170
Why?
Cell Survival
1
2020
121
0.170
Why?
Isoflavones
1
2000
2
0.170
Why?
Estrogen Receptor alpha
1
2019
16
0.160
Why?
Gene Expression Regulation, Neoplastic
1
2020
116
0.160
Why?
Cohort Studies
4
2019
1890
0.160
Why?
Gene Targeting
1
2019
10
0.160
Why?
Folic Acid Deficiency
1
2019
7
0.160
Why?
Phthalazines
1
2019
6
0.160
Why?
TOR Serine-Threonine Kinases
1
2019
13
0.160
Why?
S Phase
1
1999
11
0.160
Why?
Gene Knockdown Techniques
1
2019
45
0.160
Why?
Fenretinide
3
2010
5
0.160
Why?
Odds Ratio
2
2018
270
0.160
Why?
Proto-Oncogene Proteins c-akt
1
2019
57
0.150
Why?
Piperazines
1
2019
85
0.150
Why?
Chimerism
1
2018
4
0.150
Why?
BRCA1 Protein
1
2018
4
0.150
Why?
BRCA2 Protein
1
2018
4
0.150
Why?
Disease Management
1
2018
102
0.140
Why?
Mammography
3
2022
47
0.140
Why?
Circulating Tumor DNA
1
2017
6
0.140
Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
2017
11
0.140
Why?
Neoplasms, Multiple Primary
1
2017
39
0.140
Why?
Stomach Neoplasms
1
2017
34
0.140
Why?
Signal Transduction
1
2019
443
0.130
Why?
Paclitaxel
4
2013
50
0.130
Why?
Practice Guidelines as Topic
2
2012
261
0.130
Why?
Menstruation Disturbances
1
1996
1
0.130
Why?
Disease Models, Animal
1
2019
599
0.130
Why?
Survivors
4
2004
70
0.130
Why?
Cytostatic Agents
1
2016
2
0.130
Why?
Ovary
1
1996
23
0.130
Why?
Randomized Controlled Trials as Topic
7
2016
292
0.130
Why?
Phosphatidylinositol 3-Kinases
1
2016
44
0.130
Why?
Aspirin
1
2016
83
0.120
Why?
Male
7
2021
14772
0.120
Why?
Gene Amplification
2
2013
21
0.120
Why?
Maytansine
1
2014
2
0.110
Why?
Patient Reported Outcome Measures
1
2018
501
0.110
Why?
Membrane Glycoproteins
1
2014
68
0.110
Why?
Mammary Neoplasms, Experimental
1
1994
2
0.110
Why?
Genes, erbB-2
2
2005
7
0.110
Why?
Lymph Nodes
2
2005
72
0.110
Why?
Animals
2
2019
3642
0.110
Why?
Estrogens
3
2000
25
0.110
Why?
Nerve Tissue Proteins
1
2014
154
0.110
Why?
Mutation
4
2018
348
0.100
Why?
Neoplasms, Second Primary
3
2000
38
0.100
Why?
Deoxycytidine
3
2011
23
0.100
Why?
Gonadotropin-Releasing Hormone
1
2012
10
0.100
Why?
Ovariectomy
1
2012
26
0.100
Why?
Clinical Trials as Topic
4
2005
216
0.100
Why?
Polymorphism, Single Nucleotide
2
2014
278
0.100
Why?
Medication Adherence
1
2012
49
0.090
Why?
Adenocarcinoma
1
1993
137
0.090
Why?
Drugs, Investigational
1
2011
5
0.090
Why?
Safety
5
2004
37
0.090
Why?
Lymphatic Metastasis
3
2005
93
0.090
Why?
Retrospective Studies
7
2022
3538
0.090
Why?
Drug Administration Schedule
4
2008
158
0.090
Why?
Diet
2
2002
220
0.080
Why?
Neoplasms, Hormone-Dependent
2
2000
2
0.080
Why?
Neoplastic Stem Cells
2
2000
6
0.080
Why?
Mastectomy
1
2009
36
0.080
Why?
Vascular Endothelial Growth Factor Receptor-2
1
2008
9
0.080
Why?
Ki-67 Antigen
2
2005
18
0.080
Why?
Severity of Illness Index
2
2005
879
0.080
Why?
Doxorubicin
2
2004
57
0.070
Why?
Protein-Tyrosine Kinases
1
2008
15
0.070
Why?
Indoles
1
2008
32
0.070
Why?
Pyrroles
1
2008
23
0.070
Why?
Antineoplastic Agents, Phytogenic
1
2007
9
0.070
Why?
Contraindications
3
1998
31
0.070
Why?
Longevity
2
2000
31
0.070
Why?
Etoposide
1
1987
27
0.070
Why?
Matrix Metalloproteinase Inhibitors
2
2004
6
0.070
Why?
Breast Self-Examination
1
2007
3
0.070
Why?
Keratin-6
1
2006
2
0.070
Why?
Keratin-5
1
2006
2
0.070
Why?
Clinical Trials, Phase II as Topic
2
2003
20
0.070
Why?
Drug Interactions
2
1998
34
0.070
Why?
Proportional Hazards Models
3
2016
347
0.060
Why?
Family
1
2007
103
0.060
Why?
Multivariate Analysis
3
2004
329
0.060
Why?
Logistic Models
3
2005
395
0.060
Why?
Patient Education as Topic
1
2007
131
0.060
Why?
Drug Evaluation
7
1989
20
0.060
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2005
137
0.060
Why?
Genetic Testing
1
2005
57
0.060
Why?
Mass Screening
2
2022
167
0.060
Why?
Cardiovascular Diseases
2
2000
321
0.060
Why?
Gene Expression Profiling
1
2005
139
0.060
Why?
Gene Expression
1
2005
199
0.060
Why?
Recurrence
1
2005
310
0.060
Why?
Double-Blind Method
2
2010
406
0.060
Why?
RNA, Messenger
1
2005
310
0.060
Why?
Capecitabine
3
2011
3
0.060
Why?
Organic Chemicals
1
2004
4
0.060
Why?
Fluorouracil
3
2011
46
0.060
Why?
Hematopoietic Stem Cell Transplantation
2
1995
109
0.050
Why?
Breast Density
1
2022
4
0.050
Why?
Hydroxamic Acids
1
2002
4
0.050
Why?
Pilot Projects
2
2020
420
0.050
Why?
Nitriles
1
2002
14
0.050
Why?
Societies, Medical
1
2003
121
0.050
Why?
Triazoles
1
2002
29
0.050
Why?
Biomarkers
2
2016
562
0.050
Why?
Heart Diseases
2
2001
62
0.050
Why?
Hospitalization
1
2004
300
0.050
Why?
Risk Factors
4
2005
2302
0.050
Why?
Vinblastine
1
1981
9
0.050
Why?
Early Detection of Cancer
1
2022
102
0.050
Why?
Feeding Behavior
1
2002
85
0.050
Why?
Checkpoint Kinase 2
1
2020
8
0.040
Why?
Genetic Predisposition to Disease
1
2022
381
0.040
Why?
Genes, p53
1
2020
18
0.040
Why?
Genotype
2
2014
346
0.040
Why?
Health Behavior
1
2002
159
0.040
Why?
Estrogens, Non-Steroidal
1
2000
1
0.040
Why?
Embryonal Carcinoma Stem Cells
1
2000
1
0.040
Why?
Phytoestrogens
1
2000
4
0.040
Why?
Selective Estrogen Receptor Modulators
1
2000
3
0.040
Why?
Gonadal Steroid Hormones
1
2000
10
0.040
Why?
Hot Flashes
1
2000
11
0.040
Why?
Plant Preparations
1
2000
7
0.040
Why?
Osteoporosis, Postmenopausal
1
2000
5
0.040
Why?
Antigens, CD
2
2017
50
0.040
Why?
In Situ Hybridization, Fluorescence
2
2013
36
0.040
Why?
Hormone Replacement Therapy
1
2000
35
0.040
Why?
Ventricular Function, Left
1
2019
38
0.040
Why?
Confidence Intervals
1
1999
94
0.040
Why?
Weight Gain
1
2000
64
0.040
Why?
Folic Acid
1
2019
21
0.040
Why?
Likelihood Functions
1
1999
27
0.040
Why?
Time Factors
2
2002
1433
0.040
Why?
Taxoids
2
2008
10
0.040
Why?
Anthracyclines
2
2008
17
0.040
Why?
Flushing
1
1998
3
0.040
Why?
Estrogen Antagonists
1
1998
3
0.040
Why?
Dyspareunia
1
1998
5
0.040
Why?
Vaginitis
1
1998
3
0.040
Why?
Primary Ovarian Insufficiency
1
1998
8
0.040
Why?
Endometrial Neoplasms
1
1998
13
0.040
Why?
Mood Disorders
1
1998
27
0.040
Why?
Magnetic Resonance Imaging
1
2022
1112
0.040
Why?
Mismatch Repair Endonuclease PMS2
1
2017
5
0.040
Why?
Pedigree
1
2017
65
0.040
Why?
Cadherins
1
2017
34
0.030
Why?
Lung Neoplasms
3
1989
552
0.030
Why?
Clinical Trials, Phase III as Topic
2
2011
14
0.030
Why?
Obesity
1
2000
311
0.030
Why?
Biopsy
1
2017
201
0.030
Why?
Osteoporosis
1
1998
77
0.030
Why?
Cardiotoxicity
1
2016
8
0.030
Why?
Drug Monitoring
1
2016
11
0.030
Why?
Sleep Wake Disorders
1
1998
123
0.030
Why?
Class I Phosphatidylinositol 3-Kinases
1
2016
9
0.030
Why?
Echocardiography
1
2016
73
0.030
Why?
Glycogen Synthase Kinase 3 beta
1
2016
13
0.030
Why?
MCF-7 Cells
1
2016
15
0.030
Why?
Proto-Oncogene Proteins p21(ras)
1
2016
21
0.030
Why?
Phosphorylation
1
2016
149
0.030
Why?
Adolescent
2
2019
2172
0.030
Why?
Biological Availability
1
2014
17
0.030
Why?
Tissue Distribution
1
2014
33
0.030
Why?
United States
2
2014
2035
0.030
Why?
Enzyme-Linked Immunosorbent Assay
1
2014
90
0.030
Why?
Neoplasms, Experimental
1
1994
10
0.030
Why?
Bone Marrow Transplantation
1
1994
22
0.030
Why?
Tumor Cells, Cultured
1
1994
129
0.030
Why?
Linear Models
1
2014
247
0.030
Why?
Incidence
1
1996
759
0.030
Why?
Genome-Wide Association Study
1
2014
280
0.030
Why?
Blood Pressure
1
2014
195
0.030
Why?
Tissue Array Analysis
1
2013
7
0.030
Why?
Vascular Endothelial Growth Factor C
1
2011
1
0.020
Why?
Neuropilin-1
1
2011
3
0.020
Why?
Neoplasms
1
1994
237
0.020
Why?
Night Blindness
1
2010
2
0.020
Why?
Cyclophosphamide
2
2004
48
0.020
Why?
Vidarabine Phosphate
1
1989
1
0.020
Why?
Arabinonucleotides
1
1989
1
0.020
Why?
Spiro Compounds
1
1989
1
0.020
Why?
Organometallic Compounds
1
1989
20
0.020
Why?
Antimetabolites, Antineoplastic
1
1989
17
0.020
Why?
Premenopause
1
2009
11
0.020
Why?
Neoplasms, Radiation-Induced
1
2009
12
0.020
Why?
Carcinoma, Renal Cell
1
1989
46
0.020
Why?
Radiotherapy Dosage
1
2009
99
0.020
Why?
Haplotypes
1
2008
58
0.020
Why?
Kidney Neoplasms
1
1989
78
0.020
Why?
Statistics, Nonparametric
1
2008
125
0.020
Why?
Erlotinib Hydrochloride
1
2008
11
0.020
Why?
Bridged-Ring Compounds
1
2008
1
0.020
Why?
Hematologic Diseases
1
2008
10
0.020
Why?
Skin Neoplasms
1
2009
80
0.020
Why?
Gastrointestinal Diseases
1
2008
30
0.020
Why?
Administration, Oral
1
2008
108
0.020
Why?
Alzheimer Disease
1
2000
2109
0.020
Why?
Fatigue
1
2008
57
0.020
Why?
Culture Media
1
1987
32
0.020
Why?
Cell Division
1
1987
86
0.020
Why?
Fibroblasts
1
1987
58
0.020
Why?
Statistics as Topic
1
1987
105
0.020
Why?
Cell Differentiation
1
1987
137
0.020
Why?
Cell Line
1
1987
273
0.020
Why?
Carcinoma, Non-Small-Cell Lung
1
1989
243
0.020
Why?
Carboplatin
1
2006
26
0.020
Why?
Thiadiazoles
1
1986
1
0.020
Why?
Poverty
1
2007
96
0.020
Why?
Illinois
1
2007
250
0.020
Why?
Cells, Cultured
1
1987
520
0.020
Why?
Probability
1
2005
88
0.020
Why?
Remission Induction
1
2005
90
0.020
Why?
Women's Health
1
2007
174
0.020
Why?
Models, Statistical
1
2005
127
0.010
Why?
Oncology Nursing
1
2004
2
0.010
Why?
Patient Selection
1
2005
194
0.010
Why?
Carcinoma, Bronchogenic
1
1983
6
0.010
Why?
Imidazoles
1
2004
59
0.010
Why?
Survival
1
2003
2
0.010
Why?
Organizational Policy
1
2003
14
0.010
Why?
Axilla
1
2002
14
0.010
Why?
Mesonephroma
1
1982
1
0.010
Why?
Maximum Tolerated Dose
1
2002
13
0.010
Why?
Expert Testimony
1
2002
12
0.010
Why?
Mediastinal Neoplasms
1
1982
11
0.010
Why?
In Situ Hybridization
1
2002
49
0.010
Why?
Tumor Suppressor Protein p53
1
2002
92
0.010
Why?
Vindesine
1
1981
2
0.010
Why?
Leukopenia
1
1981
7
0.010
Why?
Neuromuscular Diseases
1
1981
5
0.010
Why?
Evidence-Based Medicine
1
2002
161
0.010
Why?
Predictive Value of Tests
1
2002
474
0.010
Why?
Multicenter Studies as Topic
1
2001
43
0.010
Why?
Salvage Therapy
1
2001
35
0.010
Why?
Fever
1
2001
34
0.010
Why?
Neoplasm Proteins
1
2001
56
0.010
Why?
Age Factors
1
2002
766
0.010
Why?
Palliative Care
1
2001
110
0.010
Why?
Cross-Sectional Studies
1
2002
891
0.010
Why?
Pain
1
2001
413
0.010
Why?
Translations
1
1997
9
0.010
Why?
Self Concept
1
1997
37
0.010
Why?
Surveys and Questionnaires
1
2002
1144
0.010
Why?
Sensitivity and Specificity
1
1997
482
0.010
Why?
Reproducibility of Results
1
1997
676
0.010
Why?
Neoplasm Invasiveness
1
1994
94
0.010
Why?
Antigens, CD34
1
1994
12
0.010
Why?
Cell Separation
1
1994
25
0.010
Why?
Cisplatin
1
1994
58
0.010
Why?
Anthracenes
1
1983
6
0.000
Why?
Tomography
1
1982
12
0.000
Why?
Radiography, Thoracic
1
1982
27
0.000
Why?
Drug Therapy, Combination
1
1982
161
0.000
Why?
Mortality
1
1982
89
0.000
Why?
Ultrasonography
1
1982
227
0.000
Why?
Cobleigh's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (330)
Explore
_
Co-Authors (20)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_